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	SOMMARIO 
	
Introduzione: L'ipertensione arteriosa polmonare è una patologia grave con una 
sopravvivenza dei pazienti stimata del 68% a 1 anno, 48% a 3 anni e il 34% a 5 
anni dalla diagnosi. Il ruolo dell’endotelina-1 è stato studiato in diverse condizioni 
patologiche tra le quali la sclerosi sistemica; nei pazienti affetti da sclerosi 
sistemica, l’endotelina-1 circolante è presente ad alto titolo suggerendo il suo 
coinvolgimento nello sviluppo del danno fibrotico e vascolare. L’endotelina-1 è, 
infatti, un peptide con attività pro-fibrotica, pertanto gli inibitori dei recettori 
endotelinici (ETA e ETB) possono esercitare un effetto anti-fibrotico. A livello 
vasale, inoltre, l'equilibrio degli effetti mediati dall’endotelina-1 sulle cellule 
muscolari lisce e sulle cellule endoteliali è responsabile dell'omeostasi del tono 
vascolare. Un altro interessante effetto dell’endotelina-1 sulle cellule endoteliali è 
l'induzione della produzione di aldosterone che, a sua volta, sembrerebbe 
incrementare i livelli di specie reattive dell'ossigeno. L'aldosterone è un mediatore 
chiave nel danno vascolare polmonare in risposta all’ipossia: l'attivazione del 
recettore per mineralcorticoidi dovuto all’aldosterone nelle cellule endoteliali in 
vitro è coinvolta nel rimodellamento vascolare e nella fibrosi in risposta all'ipossia 
e l’utilizzo di antagonisti aldosteronici attenua questi fenomeni. 
Metodi: Per valutare l'espressione delle due isoforme recettoriali dell’endotelina-1 
e del recettore per mineralcorticoidi, sono state effettuate analisi di reverse 
transcriptase-PCR, western blot e citofluorimetria. L'attivazione dei fibroblasti è 
stata valutata misurando con kit ELISA la quantità di collagene-1, TGF-β e PDGF 
nel terreno di coltura. La rilevazione della formazione di stress ossidativo 
intracellulare è stata valutata con citometria a flusso misurando la fluorescenza 
emessa dalla CM-H2DCFDA dopo incubazioni lunghe o brevi con endotelina-1 e i 
suoi inibitori recettoriali o con l’aldosterone e il suo antagonista. 
Risultati: Entrambi i recettori per l’endotelina-1 sono presenti sulla superficie dei 
fibroblasti polmonari umani e dei fibroblasti dermici normali umani disponibili in 
	commercio, ma anche su quella dei fibroblasti dermici ottenuti da donatori sani e 
da pazienti sclerodermici. L’espressione del recettore per mineralcorticoidi è stata 
rilevata nei fibroblasti polmonari umani, nei fibroblasti dermici sclerodermici e 
nelle cellule endoteliali polmonari umane mentre nei fibroblasti dermici normali 
umani e in quelli da donatori sani, la quantità di proteina recettoriale rilevata è 
stata più bassa che nelle altre cellule analizzate. Nei fibroblasti polmonari umani, 
in quelli dermici sclerodermici e nelle cellule endoteliali polmonari umane, 
l’endotelina-1 ha stimolato la produzione di specie reattive dell’ossigeno dopo 
incubazioni lunghe; tale produzione è stata inibita dall’utilizzo del bloccante per il 
recettore ETB. L’aldosterone invece, ha stimolato la produzione di specie reattive 
dell’ossigeno dopo brevi incubazioni nei fibroblasti polmonari umani, in quelli 
dermici sclerodermici e nelle cellule endoteliali polmonari umane ma non nei 
fibroblasti dermici umani normali e in quelli dermici da donatori sani. Analoghi 
risultati sono stati ottenuti nei fibroblasti polmonari umani, in quelli dermici 
sclerodermici e nelle cellule endoteliali polmonari umane stimolandoli a lungo 
con endotelina-1 in presenza o assenza dell’inibitore del recettore per 
mineralcorticoidi. 
Conclusioni: Questi risultati suggeriscono che l'endotelina-1 attiva i fibroblasti e 
la produzione di aldosterone, il vero responsabile dello stress ossidativo. 
L'inibizione della produzione di specie reattive dell'ossigeno dovuta all’utilizzo 
dell'antagonista del recettore ETB, indica che tale recettore è implicato in questo 
processo. Sono state trovate differenze nella produzione di stress ossidativo dopo 
stimolazione con endotelina-1 tra i fibroblasti dermici ottenuti da donatori sani e 
quelli da pazienti sclerodermici. Inoltre, negli stessi tipi cellulari, sono state 
evidenziate differenze nella presenza del recettore per mineralcorticoidi. 
  
	ABSTRACT 
	
Background: Pulmonary arterial hypertension is a devastating disease with an 
estimated patients’ survival of 68% at 1 year, 48% at 3 years and 34% at 5 years 
from diagnosis. The role of endothelin-1 has been studied in different conditions 
including systemic sclerosis. In systemic sclerosis patients, circulating endothelin-
1 is present at high levels, suggesting its involvement in the development of 
fibrotic and vascular damage. Indeed endothelin-1 is a potent pro-fibrotic peptide 
and inhibitors of endothelin-1 receptors (ETA and ETB) may exert an anti-fibrotic 
effect. The balance of endothelin-1 effects on smooth muscle cells and on 
endothelial cells is responsible for the homeostasis of vascular tone. Another 
interesting effect of endothelin-1 is the induction of aldosterone in endothelial 
cells that eventually results in the production of reactive oxygen species. 
Aldosterone is a key mediator of the pulmonary vascular injury response to 
hypoxia: mineralocorticoid receptor activation by aldosterone is involved in the 
remodeling/fibrosis response to hypoxia in endothelial cells in vitro and 
aldosterone antagonism attenuates these events. 
Methods: Reverse transcriptase-PCR, western blot and cytofluorimetric analyses 
were performed to evaluate the expression of the two isoforms of endothelin-1 
receptors and mineralocorticoid receptor. Activation of fibroblast was evaluated 
measuring the amount of collagen-1, TGF-β and PDGF with ELISA kits. The 
detection of intracellular oxidative stress formation was measured with flow 
cytometry using fluorescence of CM-H2DCFDA after long or short incubations 
with endothelin-1 and its receptors inhibitors or with aldosterone and its 
antagonist. 
Results: Both endothelin-1 receptors are present in commercially available human 
pulmonary fibroblasts and normal human dermal fibroblasts, human dermal 
fibroblasts from healthy donors and scleroderma human dermal fibroblasts. 
Mineralocorticoid receptor expression was detected in human pulmonary 
fibroblasts, scleroderma human dermal fibroblasts and human pulmonary artery 
	endothelial cells while in normal human dermal fibroblasts and human dermal 
fibroblasts from healthy donors the amount of this receptor was lower than the 
other cells analyzed. In human pulmonary fibroblasts, scleroderma human dermal 
fibroblasts and human pulmonary artery endothelial cells, endothelin-1 stimulates 
the production of reactive oxygen species after a long incubation. In addition, the 
production of oxygen radicals is inhibited by the use of ETB antagonist. 
Interestingly, aldosterone stimulates the production of reactive oxygen species 
after a short incubation in human pulmonary fibroblasts, scleroderma human 
dermal fibroblasts and human pulmonary artery endothelial cells, but not in 
normal human dermal fibroblasts and human dermal fibroblasts from healthy 
donors. The same results were obtained by human pulmonary fibroblasts, 
scleroderma human dermal fibroblasts and human pulmonary artery endothelial 
cells stimulated with endothelin-1 for long time with mineralocorticoid receptor 
inhibitor. 
Conclusions: These results suggest that endothelin-1 activates fibroblasts and the 
production of aldosterone, the true responsible for oxidative stress. The inhibition 
of reactive oxygen species production using the ETB antagonist indicates that the 
ETB receptor is implicated in this process. Moreover we found differences 
between fibroblasts from healthy donors and from scleroderma patients in 
oxidative stress production after endothelin-1 stimulation. Finally we found 
differences in mineralocorticoid receptor presence in the same cell types. 
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1. INTRODUCTION 
 
1.1 Pulmonary arterial hypertension 
Pulmonary hypertension (PH) is a disorder that may complicate different 
cardiovascular and respiratory diseases. The definition of PH is purely 
hemodynamic: detection of mean pulmonary artery pressure (PAPm) ≥25 mmHg 
at rest measured by right heart catheterization (RHC) [1]. The normal PAPm at 
rest is 14±3 mmHg with an upper normal limit of 20 mmHg while values between 
21 and 24 mmHg have an unclear clinical significance [1, 2]. Pulmonary arterial 
hypertension (PAH) is defined as a condition hemodynamically characterized by 
the presence of pre-capillary PH, with a pulmonary artery wedge pressure 
(PAWP) ≤15 mmHg and a pulmonary vascular resistance (PVR) >3 WU in the 
absence of other causes of pre-capillary PH [1]. Combining parameters as PAP, 
PAWP, PVR, cardiac output and pressure gradient (DPG) it is possible to have 
different hemodynamic definitions of PH (Table 1) [1, 3]. 
The clinical classification of PH takes into account multiple clinical 
conditions sharing similar presentation, hemodynamic characteristics and 
treatment strategy. The first classification of PH was proposed in 1973. In 2008, 
the 4th World Symposium on PH held at Dana Point (California, USA) revised 
previous classifications [4] and in 2013, the 5th World Symposium on PH, held in 
Nice (France), slightly modified the Dana Point classification, (Table 2) 
maintaining the division into 5 subgroups [5]: 1) pulmonary arterial hypertension 
(PAH); 2) pulmonary hypertension due to left heart disease; 3) pulmonary 
hypertension due to lung diseases and/or hypoxia; 4) chronic thromboembolic 
pulmonary hypertension (CTEPH); 5) pulmonary hypertension with unclear 
multifactorial mechanisms. 
The diagnosis of PH needs a comprehensive set of hemodynamic 
investigation to confirm the clinical suspicion and requires expertise in 
cardiology, imaging and respiratory medicine. A multidisciplinary team is 
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particularly important to identify patients with different causes of PH; for this 
reason, a diagnostic algorithm has been proposed (Figure 1) [6]. PH incidence 
data at the global level are poor because PH is present in many conditions and it 
can be asymptomatic or with few non-specific symptoms in the early stages [5]. 
Focusing our attention on PAH, in Europe its prevalence and incidence are in the 
range of 15–60 subjects per million population and 5–10 cases per million per 
year, respectively [7]. Therefore PAH is considered a rare disease with an 
estimated patients’ survival of 68% at 1 year, 48% at 3 years and 34% at 5 years 
from diagnosis [8]. 
The treatment of PAH patients can be divided into three main steps [9]: 1) 
general measures (physical activity, elective surgery, avoidance of pregnancy and 
post-menopausal hormonal therapy, infection prevention, psychosocial support); 
2) supportive therapy (oral anticoagulants, diuretics, oxygen, cardiovascular 
drugs, iron substitution); 3) specific drugs therapy (calcium channel blockers, 
endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and guanylate 
cyclase stimulators). 
Each of the five PH groups is characterized by a specific histological and 
morphological pattern [10, 11]. In PAH distal sections of pulmonary artery with a 
diameter of less than 500 µm (40-300 µm) are involved. The principal element is a 
pathophysiological vascular remodeling (Figure 2) with a strong increase in 
thickness of the muscular media, the proliferation of the intima (neo-intima 
formation), eccentric or concentric fibrotic changes, thickening adventitia with 
perivascular inflammatory infiltrates, plexiform lesions with a classic look to 
onion-layering (30-60% of patients) and the presence of small thrombi (40-50% 
of patients). It is important to underline that the veins are never affected by these 
structural changes while the arterioles and the small arteries are interested by a 
major reduction in their lumen [12, 13]. 
The mechanisms that contribute to PAH are complex and not clearly 
defined. It is believed that etiology is multifactorial including genetic, 
autoimmune, biochemical and environmental factors [14]. However there are 
three mechanisms which, taken together, produce the increase in pulmonary 
	 10	
vascular resistance: the vasoconstriction, the remodeling of the vascular wall and 
in situ thrombosis [15]. Therefore the increase of the vascular resistance is 
determined by functional and anatomical phenomena (Figure 3) [16]. 
 
1.2 Systemic sclerosis 
Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune disease of 
unknown origin, characterized by immune dysregulation, vasculopathy and multi-
organ fibrosis. Severe and diffuse endothelial cell (EC) damage and fibroblasts 
activation with overproduction and accumulation of collagen and other 
extracellular matrix proteins lead to skin thickening and fibrosis of the affected 
organs [17]. Three are the main pathogenetic mechanisms involved in this disease: 
1) vascular dysfunction and injury; 2) activation of the immune system; 3) 
increased collagen secretion by fibroblasts. 
The standard classification criteria for SSc have been recently revised by 
the American College of Rheumatology (ACR) and the European League Against 
Rheumatisms (EULAR). These criteria identify three different forms of the 
disease [18, 19]: 1) localized cutaneous scleroderma; 2) SSc; 3) overlap 
syndromes. Localized scleroderma, more common in childhood, is characterized 
only by skin involvement and rarely the disorder is systemic [20, 21]. SSc is 
characterized by the involvement of skin and different internal organs. 
Considering the cutaneous extension of fibrosis, SSc can be defined as: limited 
SSc (lSSc) with skin thickening of the face and distal part of the limbs; diffuse 
SSc (dSSc) characterized by a cutaneous thickening that also involves the 
proximal portions of the limbs and often the trunk and abdomen. The diagnosis of 
overlap syndrome can be performed when the criteria for diagnosis of SSc and of 
another autoimmune disease (systemic lupus erythematosus, Sjögren's syndrome, 
rheumatoid arthritis and other types of connectivitis) are present. 
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The epidemiology of SSc is difficult to estimate because of the differences 
in the geographical area, the disease definition and the method of case 
ascertainment [22]. The SSc prevalence in global population is estimated to be 50-
300 cases per million inhabitants with an incidence ranging of 2.3-22.8 cases per 
million per year [23]. The disease has a female/male ratio varying from 3:1 to 
14:1 according to different studies with its onset between the third/fifth decade of 
life. The higher incidence has been reported in a Choctaw Native American group 
in Oklahoma [24, 25]. 
SSc etiology is not fully known yet. Genetic and environmental factors 
play an important role in the etiopathogenesis of the disease [26-28] resulting in 
the three fundamental aspects of the disease: 1) the vasculopathy; 2) the 
alterations of cellular and humoral immune response; 3) the excessive deposition 
of collagen and other extracellular matrix proteins. 
The primary event in SSc pathogenesis is the vascular damage that is a 
systemic process which involves the small blood vessels evolving in fibrosis [29-
31]. The first cells involved in scleroderma damage are the ECs with an increased 
expression of adhesion molecules responsible for: leukocytes recruitment and 
activation; basal lamina thickening; pericytes, fibroblasts and smooth muscle cells 
(SMCs) proliferation; platelet adhesion and activation; formation of perivascular 
infiltrate [29, 32, 33]. 
 
1.3 Endothelin-1 
Endothelin-1 (ET-1) is a small peptide of 21 amino acids with a 
hydrophobic C-terminus and two cysteine bridges at the N-terminus [34]. It is 
mainly a vasoconstrictor mediator but other effects have been described. Indeed it 
plays a role in inflammation, cell adhesion, fibrosis and angiogenesis [35]. ET-1 
was isolated from cultured porcine aortic ECs in 1988 and 1 year later, two 
structurally related peptides, differing by two and six amino acids, were identified 
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and termed endothelin-2 (ET-2) and endothelin-3 (ET-3) respectively (Figure 4) 
[34, 36]. Nowadays four isoforms of endothelin are known: ET-1, ET-2, ET-3 and 
ET-4. ET-1 is produced by a large number of cells (SMCs, fibroblasts, 
myofibroblasts, mastocytes, monocytes/macrophages, polymorphonucleate cells, 
dendritic cells and others); ET-2 is mainly produced by intestinal and renal cells; 
high levels of ET-3 are found in central nervous system; little is known about ET-
4 (Table 3). It has been shown that ET-1 plays an important role in cardiovascular, 
renal and pulmonary pathologies (PH included), carcinogenesis and fibrosing 
diseases (including SSc) [34, 37-39]. 
The gene encoding for ET-1 is located on the short arm of chromosome 6 
and the activation of this gene is regulated by transcription factors as c-fos, c-jun, 
NFkB-1, AP-1 and GATA-2. PreproET-1 undergoes post-traductional 
modifications by two proteases (furin-like endopeptidase) becoming PreET-1 and 
then BigET-1. In the extracellular compartment BigET-1 is converted in ET-1 
(Figure 5) [34]. The production of this peptide is stimulated by hypoxia, exposure 
to cold, low wall tension, angiotensin II, growth factors and cytokines [37, 38]. 
ET action is mediated by its three G-protein-coupled receptors: ETA, ETB 
and ETC. ETA binds ET-1 and ET-2 with higher avidity than ET-3 but it is more 
specific for ET-1. ETB binds ET-1, ET-2 and ET-3 with the same specificity. 
Little is known about ETC. ET receptors are expressed on various cell types. The 
type of receptor bound, the cell type stimulated and the tissue conditions modulate 
the different effects of this peptide [34, 35, 39, 40]. 
ECs express exclusively ETB, while SMCs express predominantly ETB. 
Generally the balance of ET-1 actions on SMCs and ECs is responsible for the 
homeostasis of vascular tone: on SMCs, ETA is responsible for contraction due to 
production of inositol 1,4,5-trisphosphate (IP3); on ECs, ETB modulates the 
contraction of SMCs with production of nitric oxide (NO) (Figure 6) [34]. 
Alteration of this balance causes vasoconstriction. Fibroblasts express both ETA 
and ETB receptors and ET-1 can activate the production of collagen and induces 
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the expression of ICAM-1. Indeed it may stimulate the transdifferentiation of 
fibroblasts into myofibroblasts [41, 42]. The ET-1 induced collagen production by 
fibroblasts is not reduced by the selective antagonism of ETA or ETB, while it is 
reduced by combined ETA/ETB antagonism that reverts the fibrotic fibroblasts 
phenotype to normal phenotype. This would suggest the presence of cross-talk 
between the two receptors [41, 43]. 
The role of ET-1 has been studied in SSc and PAH because SSc and/or 
PAH patients present elevated ET-1 levels suggesting the involvement of this 
peptide in the development of fibrotic and vascular events [44-46]. Indeed the 
ETA/ETB antagonist Bosentan has been used as a novel anti-fibrotic drug 
contrasting the potent pro-fibrotic effect of ET-1 [47]. In a rat model, ET-1 
induces the redistribution of endothelial nitric oxide synthase (eNOS) uncoupling 
from the plasma membrane to the mitochondria in pulmonary arterial endothelial 
cells (PAECs); also ET-1 disturbed carnitine metabolism, resulting in the 
attenuation of mitochondrial bioenergetics. However, ATP levels are unchanged 
due to a compensatory increase in glycolysis [48]. Another interesting aspect of 
high levels of ET-1 is the production of aldosterone in ECs that eventually results 
in the production of reactive oxygen species (ROS). ROS block the interaction 
between ETB and eNOS reducing the Cys405 in ETB, important for the activation 
of eNOS [35]. 
 
1.4 Aldosterone 
Aldosterone is the main steroid mineralocorticoid hormone synthetized in 
the glomerular zone of the adrenal cortex in response to sodium depletion or 
hyperkaliemia but a local production of this hormone may also occur in peripheral 
tissue; it is the last product of the renin-angiotensin-aldosterone system (RAAS) 
activation [49]. The pivotal role played by RAAS is the maintenance of sodium 
and water balance through its action on kidney [50]. In response to a decrease in 
circulating blood volume (as blood loss, dehydration, ventricular pump failure) 
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the RAAS regulates intravascular volume releasing renin into circulation. The 
juxtaglomerular cells of the kidney release renin to increase angiotensin II that 
increases blood pressure by stimulating aldosterone production from the adrenal 
gland (Figure 7) [51]. 
Aldosterone has different genomic and non-genomic effects. The genomic 
effects are mediated by the intracellular mineralocorticoid receptor (MCR) and 
they include increasing in protein synthesis, inflammation and fibrosis. The 
genomic effects can be divided into classical and non-classical effects played in 
the renal distal convoluted tubule level and in different organs respectively [52-
54]. The little known non-genomic effects are mediated by a membrane receptor 
of unknown nature and they include increasing in tyrosine phosphorilation, 
activation of inositol phosphate, increasing in sodium/hydrogen exchange and 
SMCs alkalinization. The non-genomic effects are principally explicates in the 
vessels [52, 55, 56]. 
There is a clear evidence that the RAAS is activated in PAH. Preclinical 
studies performed in a rat model with PH demonstrated an increase of 
angiotensin-converting enzyme (ACE) expression with an approximately 50% 
increase in ACE activity in pulmonary vessels [57]. Nowadays different studies 
suggest aldosterone as a mediator of the cardiopulmonary vascular phenotype in 
PAH; indeed high aldosterone levels have been detected in experimental models 
of PAH and in patients affected by the disease. This is a consequence of increased 
adrenal production of aldosterone but also of extra-adrenal synthesis of the 
hormone that has been identified in the pulmonary vasculature [35, 58, 59]. 
ET-1, which is upregulated in PAH, is known to induce the production of 
aldosterone. Indeed hyperaldosteronism in PAH is confirmed [60]. These 
persistently elevated aldosterone levels activate MCR that is expressed in vascular 
and cardiac cells contributing to vascular remodeling, altered vascular reactivity 
and cardiac dysfunction. In the PAH rat monocrotaline model, ET-1 levels in 
plasma and lungs are increased; this is associated with high aldosterone levels in 
the same fluid/tissue. ET-1 is able to stimulate extra-adrenal pulmonary 
aldosterone synthesis increasing pulmonary endothelial expression of aldosterone 
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synthase (CYP11B2). In this model the mineralocorticoid receptor antagonists 
spironolactone or eplerenone decrease the number of muscularized vessels and 
limit vascular collagen deposition [35]. 
 
1.5 Reactive oxygen species 
ROS are chemically reactive molecules containing oxygen constantly 
formed in the body and removed by antioxidant defenses preventing their 
formation or repairing the damage that they induce [61]. ROS, but also reactive 
nitrogen species (RNS), play a dual role having both deleterious and beneficial 
effects. ROS and RNS are generated by regulated enzymes as NO synthase (NOS) 
and NADPH oxidase isoforms respectively. Low/moderate concentrations of 
ROS/RNS have beneficial effects in physiological processes, for example in 
defense against infectious agents, in cellular signaling pathways and in induction 
of a mitogenic response. In contrast, overproduction of ROS results in oxidative 
stress, a deleterious process responsible for cell damage [62]. The paracrine action 
of endothelium-derived NO controls vascular tone, inhibits platelet function, 
prevents leukocytes adhesion and reduces intima proliferation. Inactivation and/or 
reduced synthesis of NO can promote vasospasm, thrombosis, vascular 
inflammation and SMCs proliferation [63]. 
Pulmonary endothelial ROS have been implicated in PAH and have been 
shown to disrupt NO-dependent vasodilatory signaling pathways to promote 
pulmonary vasoconstriction, muscularization of pulmonary arterioles and 
perivascular fibrosis [64, 65]. Activation of eNOS mediated by ETB results in a 
production of endogenous NO in pulmonary tissue [66] but how ROS decrease the 
production of NO in PAH is not clear. ETB contains an intracellular cysteine-rich 
region near its C-terminus (Figure 8) [67], in this domain there is Cys405, 
demonstrated to be a cysteinyl thiol that regulates ETB signal transduction [68]. In 
a model proposed by Maron et al. (Figure 9) [35], the oxidative modification of 
Cys405 by aldosterone-induced ROS disables ETB-eNOS activation promoting 
pulmonary vascular dysfunction in pulmonary artery endothelial cells (HPAECs). 
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2. AIM OF THE PROJECT 
	
ET-1 plays a pivotal role in the three major aspects involved in the 
pathogenesis of SSc and PAH: vasoconstriction, fibrosis and inflammation. At the 
moment we know that ET-1 is responsible of dysregulation of vascular tone and, 
consequently, of endothelial cell damage. Indeed ET receptors are expressed on 
the majority of cells involved in SSc and PAH, such as ECs, SMCs and 
fibroblasts; for this reason ETA/ETB antagonists are used in treatment of SSc 
patients with recurrent ischemic digital ulcers and/or PAH with beneficial effects 
on fibrosis and vasoconstriction. A recent study has revealed that ET-1 is able to 
increase the aldosterone production in pulmonary ECs and that this hormone is 
responsible for the formation of ROS. 
The aim of this PhD project was to clarify the role of ET-1 in the 
pathogenesis of PAH and to investigate the effects of this molecule on pulmonary 
vascular cells analyzing its effects on lung fibroblasts and ECs. We have also 
studied the effects of ET-1 on fibroblasts derived from skin of SSc patients and 
healthy donors. This study was based on the hypothesis that ET-1 could have a 
fundamental role on ROS production and fibroblasts activation. For this reason we 
have analyzed the effects of ET-1 stimulation on fibroblasts and oxidative stress 
production; moreover we have investigated the link between ET-1 and 
aldosterone. 
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3. MATERIALS AND METHODS 
 
3.1 Cell cultures and treatments 
This study was performed using human pulmonary fibroblasts (HPFs), 
normal human dermal fibroblasts (NHDFs) and human pulmonary artery 
endothelial cells (HPAECs) (PromoCell, Heidelberg, Germany). Moreover dermal 
fibroblasts from healthy donors (HDFs) and from SSc patients (SSc HDFs) 
obtained by skin biopsy were used. Cells were grown to confluence at 37°C and 
5% CO2 by using fibroblast growth medium 2 and endothelial growth medium 
(PromoCell) for the commercial lines while in DMEM (ThermoFischer 
Scientific/Gibco, Waltham, MA, USA) +10% FBS (Sigma-Aldrich, St. Louis, 
MO, USA) +1% penicillin streptomycin (pen-strep; ThermoFischer 
Scientific/Gibco) for the cells from skin biopsy. Cells were passaged by using 
accutase (Millipore, Billerica, MA, USA) and experiments were performed on 
cells from passages 4 to 10. 
ET-1 (100 nM) (Tocris Bioscience, Bristol, UK ) and BQ123 (1.5 µM) 
(Sigma-Aldrich), a selective ETA endothelin receptor antagonist, were dissolved 
in RPMI (Lonza, Basel, Switzerland); BQ788 (1.5 µM) (Sigma-Aldrich), a 
selective ETB endothelin receptor antagonist, aldosterone (100 nM) (Sigma-
Aldrich) and the MCR inhibitor spironolactone (10 µM) (Sigma-Aldrich) were 
dissolved in DMSO (Sigma-Aldrich). 
 
3.2 HDFs isolation 
HDFs were isolated from skin biopsies of healthy donors and of limited 
cutaneous SSc patients who kindly offered a skin sample for research purposes 
after written informed consent. Biopsy samples (0.6 cm of the forearm skin) were 
placed immediately in DMEM +1% pen-strep. In sterile hood, the skin samples 
were transferred in 1 mL digestion medium (DMEM +20% FBS +0.25% 
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collagenase type I +0.05% DNAse I +1% pen-strep) than they were placed 
overnight in 37°C tissue culture incubator (collagenase type I and DNAse I were 
purchased from Sigma-Aldrich). Next day, the samples were vortexed for 20 
seconds and, in sterile hood, 7 mL of culture medium (DMEM +20% FBS +1% 
pen-strep) were added. Then entire contents were transferred in T75 tissue culture 
flasks (BD Bioscience/Falcon, San Josè, CA, USA) that were placed in 37°C 
tissue culture incubator for 72 hours. On day 6, 7 mL of culture medium (DMEM 
+10% FBS +1% pen-strep) were added. After cells were passaged for the first 
time, the culture medium used was DMEM +10% FBS +1% pen-strep. 
 
3.3 RNA isolation and RT-PCR 
HPFs, NHDFs and HPAECs were cultured in 6-wells plates (BD 
Bioscience/Falcon) and were stimulated by ET-1 for 24 hours. Using TRI Reagent 
(Sigma-Aldrich) total RNA was obtained and then used for retrotranscription in 
cDNA. Amplification of cDNA was performed using AmpliTaq Gold PCR 
MasterMix (Applied Biosystems, Foster City, CA, USA) and GenAmp PCR 
System 9700 thermocycler (Applied Biosystems). The following primers (Sigma-
Aldrich) were used for ETA, ETB, MCR and α-SMA detection: 
ETA: forward 5'-ATGCACAACTATTGCCCACA-3'  
  reverse 5'-GGACAGGATCCAGATGGAGA-3' 
ETB: forward 5'-GCACATCGTCATTGACATCC-3'  
  reverse 5'-CAGAGGGCAAAGACAAGGAC-3' 
MCR: forward 5'-AGGCTACCACAGTCTCCCTG-3'  
  reverse 5'-GACTGGAGATTTTACACTGC-3' 
α-SMA: forward 5'-GGAATCCTGTGAAGCAGCTC-3'  
  reverse 5'-GAAGGAATAGCCACGCTCAG-3' 
Vimentin was used as internal control. 
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3.4 Western blot analysis 
NaCl, TRIS, Tween 20, MgCl2, β-mercaptoethanol, glycine, glycerol, 
bromphenol blue, sodium dodecil sulphate (SDS), 30% acrylamide/bis solution, 
methanol, ammonium persulfate (APS) were purchased by Sigma-Aldrich; temed 
was purchased from GE Healthcare Life Biosciences (Little Chalfont,UK); 
Dulbecco’s phosphate buffered saline (DPBS) was from Lonza. 
Western blot analyses were performed to confirm the expression of ETA 
and ETB receptors on cell surface but also to evaluate the presence of MCR and 
CYP11B2 in the intracellular space. Total protein lysate was obtained using RIPA 
buffer +1% protease inhibitors mix (Roche, Penzberg, Germany). Equal amounts 
of protein samples (20 µg) were separated by electrophoresis with 10% 
acrylamide gel under reducing conditions and transferred to nitrocellulose 
membrane (GE Healthcare Life Biosciences/Amersham Biosciences, Little 
Chalfont, UK). Membranes were then incubated in blocking buffer containing 5% 
non-fat dry milk powder (Sigma-Aldrich). ETA, ETB, MCR and CYP11B2 were 
detected incubating the membrane with 1:100 polyclonal primary antibody anti-
ETA (Acris Antibodies, GmbH, Herford, Germany) or 1µ/ml polyclonal anti-ETB 
(Lifespan Biosciences, Seattle, WA, USA) or 1:500 polyclonal primary antibody 
anti-MCR (Abcam, Cambridge, United Kindom) or 1:60 polyclonal primary 
antibody anti-CYP11B2 (Abcam) overnight at 4°C. 1:100 polyclonal primary 
antibody anti-b-actin (Sigma-Aldrich) was used as internal control. Membranes 
were then incubated with a 1:3000 anti-rabbit IgG-HRP for ETA (GE Healthcare, 
Freiburg, Germany) or a 1:3000 anti-sheep IgG-HRP for ETB (Bethyl 
Laboratories, Inc. Montgomery, TX, USA) or 1:1000 anti-rabbit IgG-HRP (Santa 
Cruz Biotechnology, Dallas, TX) for MCR, CYP11B2 and b-actin for 1 hour at 
room temperature. The detection was performed using the ECL detection system 
(GE Healthcare Life Biosciences/Amersham Biosciences) and the Image Quant 
Las Mini 4000 Digital Imaging System (GE Healthcare Life Sciences) while 
densitometric analysis was carried out using the ImageQuant TL software (GE 
Healthcare Life Sciences). 
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3.5 Flow cytometry 
Flow cytometry was used to detect the presence of ETA and ETB receptors 
on cell surface and to evaluate the oxidative stress induced by ET-1 or 
aldosterone. Samples were acquired with a FACSCanto II cytometer (BD 
Bioscience) and data were analyzed by FlowJo software (Treestor, Ashland, OR, 
USA). 
Cells were incubated with anti-ETA or anti-ETB polyclonal primary 
antibody used also for western blot analyses and stained with R-Phycoerythrin 
(PE) secondary monoclonal anti-rabbit or anti-sheep IgG (R&D Systems, 
Minneapolis, MN, USA) respectively; cells incubated only with secondary 
antibodies were used as negative controls. 
The detection of intracellular oxidative stress formation was based on the 
oxidation of 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA; Invitrogen, Oregon, USA) 50 µM dissolved in DMSO to yield 
an intracellular-trapped fluorescent compound. This molecule is extremely 
sensitive to changes in the redox state of cells and can be used to follow changes 
in ROS over time. Its fluorescence was measured with flow cytometry after short 
(40 minutes) or long (24 hours) stimulation with ET-1 in cells grown with 10% 
human serum (Invitrogen) and after incubation with CM-H2DCFDA for 30 
minutes. To evaluate the role of individual receptor engagement, cells were also 
pre-incubated with BQ123 and/or BQ788 for 30 minutes. ROS production was 
also evaluated after short stimulation with aldosterone (40 minutes) and after pre-
incubation with spironolactone (30 minutes). In addiction, cells underwent long 
ET-1 stimulus (24 hours) and concurrently incubated with spironolactone. In 
every experiment H2O2 was used as internal positive control and washes were 
performed using Hank’s balanced salt solution (HBSS; ThermoFischer 
Scientific/Gibco). 
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3.6 ELISA kit 
The HPFs and NHDFs supernatant concentrations of collagen-1, TGF-β 
and PDGF were measured by enzyme-linked immunosorbent assay (ELISA) 
before ad after 24- or 48-hour stimulation with ET-1. Collagen-1 ELISA kit was 
purchased by BlueGene Biotech (Shanghai, China) while TGF-β and PDGF 
ELISA kits by R&D Systems. The samples preparation and the assay were 
performed following the manufacturer’s recommendations. The enzymatic 
reaction optical densities were determined reading the plates at 450 nm with 
TECAN Sunrise III (Tecan, Männedorf, CH). 
 
3.7 Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 5 
(GraphPad Software Inc., La Jolla, CA, USA). Data with a normal distribution 
were analyzed with Student’s t-test and were expressed as a mean ± standard 
deviation. A difference between groups with a p<0.05 was considered statistically 
significant. 
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4. RESULTS 
	
4.1 ET-1 receptors 
The presence of the two ET receptor isoforms (ETA and ETB) in HPFs was 
carried out at two levels: at transcriptional level evaluating the presence of 
ETA/ETB mRNA by RT-PCR; at protein level by flow cytometry and western blot 
analysis in order to confirm the expression of ET receptors on the cell surface. 
The potential expression differences in the same cells from different tissues were 
analyzed by RT-PCR and flow cytometry using also NHDFs. The presence of ET 
receptors in HDFs and SSc HDFs was performed on these cells by flow cytometry 
and western blot analysis. We found that all the fibroblasts tested express both 
ETA and ETB (Figure 10). We did not perform this analysis on HPAECs since it is 
well known from the literature only the presence of the ETB receptor [34, 35]. 
 
4.2 MCR and CYP11B2 
The presence of MCR mRNA was detected in HPFs, NHDFs and HPAECs 
by means of RT-PCR. HPFs and HPAECs showed the presence of mRNA for this 
receptor while it seems not to be present in NHDFs. After isolation of HDFs and 
SSc HDFs, western blot analyses were carried out on HPF, HDFs, SSc HDFs and 
HDAECs. The western blot analyses showed the presence of MCR in all the cell 
types analyzed with a difference of expression between HDFs and SSc HDFs 
(Figure 11). 
To better understand the aldosterone biogenesis pathway, the presence of 
CYP11B2 was evaluated in HPF, HDFs, SSc HDFs and HDAECs by western blot 
analysis. All these cells showed the presence of this enzyme in equal amount 
(Figure 11B). 
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4.3 ET-1 effects on MCR and α-SMA 
The presence of MCR and α-SMA mRNA was evaluated by RT-PCR in 
HPFs, NHDFs and HPAECs stimulated by ET-1 for 24 hours (Figure 12). The 
mRNA amounts do not change before and after stimulation with ET-1. 
 
4.4 Activation of fibroblasts 
In order to evaluate the activation of fibroblasts, protein levels of PDGF, 
collagen-1 and TGF-β were tested in the supernatants of HPF and NHDF cultures 
before and after stimulation with ET-1 for 24 or 48 hours using commercial 
ELISA kits (Figure 13). The data obtained are reported in Table 4 and the 
statistical analysis shows significant differences in: HPFs collagen-1 production 
only after 24 hours of incubation with ET-1 (p<0.0001); NHDFs collagen-1 
production after 24 and 48 hours (p<0.0001 and p<0.0002 respectively); HPFs 
TGF-β production after 24 and 48 hours (p<0.0006 and p<0.0013 respectively); 
NHDFs TGF-β production after 24 and 48 hours (p<0.0001 and p<0.0392 
respectively); PDGF production in both HPFs and NHDFs only after 24 hours of 
incubation (p<0.0001). 
 
4.5 Oxidative stress 
The production of ROS was analyzed with CM-H2DCFDA, a 
chloromethyl derivative of H2DCFDA that passively diffuses into cells, where its 
acetate groups are cleaved by intracellular esterases and its thiol-reactive 
chloromethyl group reacts with intracellular glutathione and other thiols; 
subsequent oxidation yields a fluorescent adduct that is trapped inside the cells. In 
HPFs, SSc HDFs and HPAECs, ET-1 stimulated the production of ROS only after 
24-hour incubation and this production was inhibited by the use of the ETB 
blocker BQ788. In NHDFs and HDFs there was absence of ROS production both 
after short and long stimulation with ET-1 (Figure 14). In HPFs, SSc HDFs and 
HPAECs, but not in NHDFs and HDFs, also aldosterone stimulated the 
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production of ROS after a short incubation of 40 minutes and this production was 
inhibited by pre-incubation with spironolactone (Figure 15). Same results were 
found in HPFs, SSc HDFs and HPAECs stimulated by ET-1 for 24 hours with or 
without spironolactone (Figure 16). 
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5. DISCUSSION AND CONCLUSIONS 
	
Since its discovery, ET-1 is known to be a vasoconstrictor mediator but 
nowadays other different effects have been identified; indeed the action of this 
peptide is involved in cell adhesion, inflammation and angiogenesis. All these 
aspects have a pivotal role in the pathogenesis of SSc but also of PAH: high levels 
of this peptide are present in the plasma, derma and internal organs of these 
patients [69-72]. The recent literature [35, 58] reports apparently contradictory 
actions of ET-1 on pulmonary ECs in vitro, while on SMCs it stimulates muscle 
contraction by binding to ETA; indeed the interaction with fibroblast stimulates 
fibrogenesis increasing production of extracellular matrix proteins. It is known 
that the ET-1 bound to ETB expressed on ECs initiates a signal cascade that 
increases NO production by eNOS activation. This fact is in contrast with the 
observation that ET-1 may represent a stimulus for the endothelial aldosterone 
synthesis through PPAR coactivator-1α, steroidogenesis factor-1 and CYP11B2. 
Therefore the produced aldosterone is able to block ETB pathway. Indeed in PAH 
patients low levels of NO are found and for this reason therapeutic agents 
mimicking the NO action have been introduced into the PAH treatment. 
The starting point of this study was the evaluation of the presence of ET-1 
receptors on analyzed cells. At the beginning, their expression was tested with 
flow cytometry and RT-PCR in HPFs and NHDFs to find possible differences in 
fibroblasts derived from different tissues. Subsequently, this analysis was 
extended also to dermal fibroblasts from skin biopsies performing flow cytometry 
and western blot analyses. The evaluation of the presence of these receptors was 
relevant for the following experiments regarding the effects of ET-1. The 
detection of the mediators and components of fibrosis (TGF-β, PDGF and 
collagen-1) production in the supernatant of dermal and lung fibroblasts revealed 
that these molecules are generally increased after stimulation with ET-1. The high 
production of collagen-1 indicates the ability of ET-1 to promote fibrosis in 
various tissues as occurs in SSc. Therefore the endothelinic stimulus increases 
synthesis of the fundamental component of the extracellular matrix and the 
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production of profibrotic molecules. The potential of dermal and lung fibroblasts 
to differentiate into myofibroblats after stimulation with ET-1 was evaluated by 
RT-PCR of mRNA encoding for α-SMA.	Transdifferentiation is a very important 
event in the pathogenesis of PAH and other fibrosing diseases. In our 
experiments, ET-1 did not change the transcription of α-SMA mRNA; our 
hypothesis is that cells need a further stimulus to start the transdifferentiation 
process. To investigate the role of aldosterone in the pathogenesis of PAH, the 
presence of the mRNA encoding for MCR was evaluated by RT-PCR in HPFs, 
NHDFs and HPAECs before and after 24-hour stimulation with ET-1: the amount 
of mRNA does not change. The presence of MCR and CYP11B2 was analyzed 
using western blot analysis in HPFs, HDFs, SSc HDFs and HPAECs; MCR was 
detected in different amount in the various cells analyzed whereas CYP11B2 did 
not behave in the same way; MCR is present in low concentration in HDFs and 
MCR mRNA was not detectable in NHDFs. All these data suggest that fibroblasts 
behavior from different body districts may be different. Through flow cytometry, 
we were able to prove that a 24-hour stimulation with ET-1 increases ROS 
production. This datum confirms that oxidative stress mediated by ET-1 is 
involved in the pathogenesis of PAH at HPAECs level. The block of ETB through 
a specific receptor blocker (BQ788) inhibited the synthesis of ROS in these cells 
that displayed an amount of ROS production similar to unstimulated cells. 
Analogous results were obtained with similar stimulation experiments conducted 
with ET-1 on HPFs that express both ETA and ETB receptors. Also in this case the 
block of ETB led to lower production of basal ROS; on the contrary the ETA block 
did not involve any effect on the synthesis of ROS after ET-1 stimulation. This 
results suggested that the ET-1/ETB interaction is important for the oxidative 
stress in both HPAECs and HPFs. Since the induction of oxidative stress needs an 
incubation of 24 hours with ET-1 it is possible that this incubation is necessary for 
the activation of signaling cascade for the synthesis of aldosterone. A very 
interesting thing is the different behavior of dermal fibroblasts derived from 
healthy donors and SSc patients. Both kinds of fibroblasts express ETA and ETB 
but only SSc HDFs showed a ROS production as HPAECs and HPFs. We have 
incubated cells with aldosterone for 40 minutes and this short incubation was 
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sufficient to induce ROS production in HPAECs, HPFs and SSc HDFs. The 
possible correlation between ET-1 and aldosterone is supported by the absence of 
ROS production when cells were incubated with spironolactone, the aldosterone 
inhibitor, and ET-1 for 24 hours. 
 
These results suggest that ET-1 is an important molecule involved in 
pathogenesis of PAH for its ability to activate fibrosis but also for its indirect role 
in oxidative stress inducing the production of aldosterone that seems to be the true 
responsible for ROS production. 
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TABLES AND FIGURES 
 
 
 
 
 
 
 
Table 1. Hemodynamic definition of pulmonary hypertension. 
Definition Characteristics Clinical group(s) 
PH PAPm ≥25 mmHg All 
Pre-capillary PH PAPm ≥25 mmHg 
PAWP ≤15 mmHg 
1. PAH 
3. PH due to lung diseases 
4. Chronic thromboembolic PH 
5. PH with unclear and/or 
multifactorial mechanisms 
Post-capillary PH PAPm ≥25 mmHg 
PAWP >15 mmHg 
2. PH due to left heart disease 
5. PH with unclear and/or 
multifactorial mechanisms 
Isolate post-capillary PH DPG <7 mmHg 
and/or PVR ≤3 WU 
 
Combined post-capillary 
and pre-capillary PH 
DPG ≥7 mmHg 
and/or PVR >3 WU 
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Table 2. Clinical classification of pulmonary hypertension (Nice, 2013). 
1. PAH 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 mutation 
1.2.2 Other mutations 
1.3 Drug and toxin induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1’. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1’.1 Idiopathic 
1’.2 Heritable 
1’.2.1 EIF2AK4 mutation 
1’.2.2 Other mutations 
1’.3 Drug, toxin and radiation induced 
1’.4 Associated with: 
1’.4.1 Connective tissue disease 
1’.4.2 HIV infection 
1’’. Persistent PH of the newborn 
2. PH due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Vascular disease 
2.4 Congenital/acquired left heart inflow/outflow tract 
2.5 Congenital/acquired pulmonary veins stenosis 
3. PH due to lung disease and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary disease with mixed respective and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung disease 
4. Chronic thromboembolic PH and other pulmonary artery obstructions 
4.1 Chronic thromboembolic PH 
4.2 Other pulmonary artery obstructions 
4.2.1 Angiosarcoma 
4.2.2 Others intravascular tumors 
4.2.3 Arteritis 
4.2.4 Congenital pulmonary arteries stenoses 
4.2.5 Parasites 
5. PH with unclear and/or multifactorial mechanisms 
5.1 Hematological disorders 
5.2 Systemic disorders, sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3 Metabolic disorders 
5.4 Others 
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Table 3. Cellular source of ET-1, ET-2 and ET-3. 
ET-1 ET-2 ET-3 
ECs Kidney epithelial cells Neuronal stromal cells 
Cardiomyocytes Cardiomyocytes Glial cells 
Aortic vascular SMCs Throphoblastic cells  Adrenal cells 
Kidney epithelial cells Uterine glandular epithelial 
cells 
Intestinal epithelial cells 
Neurosecretory nerve 
endings in neurohypophysis  
Gastroentestinal stromal 
cells 
Kidney epithelial cells 
Astrocytes  Lung epithelial cells 
Kidney mesangial cells   
Sertoli cells   
Endometrial cells   
Breast epithelial cells   
Leukocytes   
Myofibroblasts   
Bile ductus epithelial cells   
Neuronal stromal cells   
 
 
Table 4. Collagen-1, TGF-β and PDGF amount in cell culture supernatants. 
HPFs CTRL 24h ET-1 24h CTRL 48h ET-1 48h 
Col-1 (ng/mL) 6.645±0.088 7.533±0.126 6.670±0.052 7.900±0.330 
TGF-β (pg/mL) 1190.047±5.263 1252.193±1.055 1276.790±0.561 1242.780±32.087 
PDGF (pg/mL) 22.550±0.362 24.215±0.066 21.058±0.413 21.068±0.413 
 
NHDFs CTRL 24h ET-1 24h CTRL 48h ET-1 48h 
Col-1 (ng/mL) 6.855±0.150 7.747±0.051 6.887±0.059 6.865±0.058 
TGF-β (pg/mL) 627.44±18.257 679.852±0.863 641.695±98.339 887.110±9.653 
PDGF (pg/mL) 20.675±0.050 22.877±0.491 24.647±0.412 24.505±0.243 
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Figure 1. Diagnostic algorithm of PH [6]. 
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Figure 2. Vascular abnormalities associated with PAH [13]. 
 
 
 
Figure 3. Pulmonary vascular remodeling in PAH [16]. 
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Figure 4. Endothelin structure [34]. 
 
 
 
Figure 5. ET-1 biosynthetic pathway [34]. 
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Figure 6. Endothelin signaling in vascular space [34]. 
 
 
 
Figure 7. The renin-angiotensin-aldosterone system. 
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Figure 8. ETB structure [67]. 
 
 
 
Figure 9. A proposed mechanism by which hyper-aldosteronism decreases NO generation 
and eNOS activation in PAH [35]. 
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Figure 10. ET receptors analyses in fibroblasts. Expression of ET receptors is analyzed with 
flow cytometry in HPFs, NHDFs, HDFs and SSc HDFs (A), RT-PCR in HPFs and NHDFs (B), 
western blot analysis in HPFs, HDFs and SSc HDFs (C). Every kind of analysis shows the 
presence of both ET receptors in the cells analyzed. 
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Figure 11. MCR and CYP11B2 expression in fibroblasts. (A) RT-PCR shows the presence of 
MCR mRNA in HPFs and HPAECs but not in NHDFs. (B) Western blot analysis confirms the 
presence of MCR in HPFs and HPAECs and shows a difference receptor amount in cells analyzed: 
SSc HDFs express MCR 1.27 times more than HPFs and 1.32 times more than HDFs; HPFs and 
HDFs show a difference of MCR expression between them of 1.03 times; HPAECs express MCR 
1.48, 1.54, 1.16 times more than HPFs, HDFs and SSc HDFs respectively. CYP11B2 amount is 
similar in every kind of analyzed fibroblasts but is 1.40 times more expressed in HPAECs. 
 
 
 
Figure 12. ET-1 effects on MCR (A) and α-SMA (B) on HPFs, NHDFs and HPAECs. RT-
PCR does not show differences in mRNA amount of MCR or α-SMA in cells analyzed after ET-1 
stimulation for 24hs. 
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Figure 13. Fibroblasts activation after ET-1 stimulation. Activation of fibroblast is analyzed 
measuring levels of collagen-1 (A), TGF-β (B) and PDGF (C) in supernatants of HPFs and 
NHDFs after 24 or 48 hours of incubation with ET-1. A stimulation of 24 hours is sufficient to 
induce the production of collagen-1, TGF-β and PDGF in HPFs and NHDFs. After 48 hours TGF-
β is released by HPFs while in NHDF supernatants collagen-1 increases together with TGF-β. 
(*** p<0.0001; ** p<0.001; * p<0.05) 
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Figure 14. Evaluation of oxidative stress after 40 minutes (A) or 24 hours (B) of ET-1 
stimulation. ET-1 stimulates ROS production only after the 24-hour incubation in HPFs, SSc 
HDFs and HPAECs; this production is inhibited by blocking ETB receptor using BQ788. In 
NHDFs and HDFs there is absence of oxidative stress formation after both short and long ET-1 
stimulation. 
	 46	
 
Figure 15. Evaluation of oxidative stress after 40 minutes of aldosterone stimulation. 
Aldosterone stimulates the production of ROS after a short incubation in HPFs, SSc HDFs and 
HPAECs, but not in NHDFs and HDFs; this production is inhibited by pre-incubation with 
spironolactone. 
	 47	
 
Figure 16. Evaluation of oxidative stress after 24 hours of ET-1 stimulation with or without 
spironolactone co-incubation. ET-1 stimulates the production of ROS after a long incubation in 
HPFs, SSc HDFs and HPAECs, but not in NHDFs and HDFs; this production is inhibited by co-
incubation with spironolactone.   
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